
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
A 50-Year-Old Woman With ALK-Rearranged NSCLC
Case: A 50-Year-Old Woman WithALK-Rearranged NSCLC


